tiprankstipranks
Hims & Hers Health, Inc. (MX:HIMS)
NYSE:HIMS
Mexico Market
HIMS
Hims & Hers Health
RESEARCH TOOLSreports

Hims & Hers Health (HIMS) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

HIMS Analyst Ratings

Moderate Buy
12Ratings
Moderate Buy
4 Buy
8 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Hims
& Hers Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HIMS Stock 12 Month Forecast

Average Price Target

$531.01
Based on 12 Wall Street analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is $531.01 with a high forecast of $697.36 and a low forecast of $366.12. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"284":"$284","508":"$508","732":"$732","956":"$956","1180":"$1,180"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":697.3622272,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$697.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":531.0122792533333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$531.01</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":366.11516928000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$366.12</span>\n  </div></div>","useHTML":true}}],"tickPositions":[284,508,732,956,1180],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,650,653.6432482461538,657.2864964923077,660.9297447384615,664.5729929846154,668.2162412307692,671.859489476923,675.502737723077,679.1459859692308,682.7892342153846,686.4324824615385,690.0757307076923,693.7189789538462,{"y":697.3622272,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,650,640.8470984041026,631.6941968082051,622.5412952123077,613.3883936164102,604.2354920205128,595.0825904246153,585.9296888287179,576.7767872328205,567.6238856369231,558.4709840410256,549.3180824451282,540.1651808492308,{"y":531.0122792533333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,650,628.1627053292308,606.3254106584616,584.4881159876923,562.650821316923,540.8135266461538,518.9762319753846,497.1389373046154,475.3016426338462,453.46434796307693,431.6270532923077,409.78975862153845,387.95246395076924,{"y":366.11516928000003,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":899.61,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1179.6,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":815,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1034,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":841.79,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":696.02,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":581.43,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":474,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":285,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":355,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":474.92,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":482.66,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":650,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$697.36Average Price Target$531.01Lowest Price Target$366.12
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MX:HIMS
Glen Santangelo
Barclays
Barclays
$679.93
Buy
―
Reiterated
07/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Molina Healthcare (NYSE: MOH)
Citi Analyst forecast on MX:HIMS
Daniel Grosslight
Citi
Citi
$488.15→$610.19
Hold
―
Reiterated
07/24/26
Hims & Hers price target raised to $35 from $28 at CitiHims & Hers price target raised to $35 from $28 at Citi
Truist Financial Analyst forecast on MX:HIMS
Jailendra Singh
Truist Financial
Truist Financial
$400.98→$470.72
Hold
―
Reiterated
07/24/26
Hims & Hers Health (HIMS) Receives a Hold from Truist Financial
Bank of America Securities Analyst forecast on MX:HIMS
Allen Lutz
Bank of America Securities
Bank of America Securities
$645.06
Hold
―
Reiterated
07/23/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Argenx Se (NASDAQ: ARGX)
Canaccord Genuity Analyst forecast on MX:HIMS
Maria Ripps
Canaccord Genuity
Canaccord Genuity
$697.36
Buy
―
Reiterated
07/23/26
Hims & Hers Health: Regulatory Tailwinds and Peptide Opportunity Support Buy Rating, $40 Price Target Reiterated
Morgan Stanley Analyst forecast on MX:HIMS
Craig Hettenbach
Morgan Stanley
Morgan Stanley
$366.12
Hold
―
Reiterated
07/22/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), TransMedics Group (NASDAQ: TMDX) and Hims & Hers Health (NYSE: HIMS)
Evercore ISI Analyst forecast on MX:HIMS
Mark Mahaney
Evercore ISI
Evercore ISI
$418.42
Hold
―
Reiterated
05/12/26
Evercore ISI Sticks to Its Hold Rating for Hims & Hers Health (HIMS)
Jefferies Analyst forecast on MX:HIMS
Brian Tanquilut
Jefferies
Jefferies
$444.57→$427.13
Hold
―
Reiterated
05/12/26
Hims & Hers price target lowered to $24.50 from $25.50 at JefferiesHims & Hers price target lowered to $24.50 from $25.50 at Jefferies
TD Cowen Analyst forecast on MX:HIMS
Jonna Kim
TD Cowen
TD Cowen
$400.98→$435.85
Hold
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW), Hims & Hers Health (NYSE: HIMS) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
J.P. Morgan Analyst forecast on MX:HIMS
Cory Carpenter
J.P. Morgan
J.P. Morgan
$610.19→$575.32
Buy
―
Reiterated
05/12/26
Hims & Hers price target lowered to $33 from $35 at JPMorganHims & Hers price target lowered to $33 from $35 at JPMorgan
Needham Analyst forecast on MX:HIMS
Ryan MacDonald
Needham
Needham
$610.19
Buy
―
Reiterated
05/12/26
Analyst Reaffirms Buy on Hims & Hers, Lifts Price Target to $35 on Long-Term Growth from Novo Partnership
Deutsche Bank Analyst forecast on MX:HIMS
George Hill
Deutsche Bank
Deutsche Bank
$488.15→$435.85
Hold
―
Assigned
05/05/26
Hims & Hers price target lowered to $25 from $28 at Deutsche BankHims & Hers price target lowered to $25 from $28 at Deutsche Bank
Leerink Partners Analyst forecast on MX:HIMS
Michael Cherny
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
04/16/26
Push to ease peptide restrictions positive for Hims & Hers, says Leerink Push to ease peptide restrictions positive for Hims & Hers, says Leerink
Nephron Analyst forecast on MX:HIMS
Unknown Analyst
Nephron
Not Ranked
Nephron
$610.19
Buy
―
Upgraded
03/09/26
Hims & Hers upgraded to Buy from Hold at Nephron ResearchHims & Hers upgraded to Buy from Hold at Nephron Research
BTIG Analyst forecast on MX:HIMS
David Larsen
BTIG
BTIG
―
Hold
―
Reiterated
03/05/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on MX:HIMS
Glen Santangelo
Barclays
Barclays
$679.93
Buy
―
Reiterated
07/24/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Molina Healthcare (NYSE: MOH)
Citi Analyst forecast on MX:HIMS
Daniel Grosslight
Citi
Citi
$488.15→$610.19
Hold
―
Reiterated
07/24/26
Hims & Hers price target raised to $35 from $28 at CitiHims & Hers price target raised to $35 from $28 at Citi
Truist Financial Analyst forecast on MX:HIMS
Jailendra Singh
Truist Financial
Truist Financial
$400.98→$470.72
Hold
―
Reiterated
07/24/26
Hims & Hers Health (HIMS) Receives a Hold from Truist Financial
Bank of America Securities Analyst forecast on MX:HIMS
Allen Lutz
Bank of America Securities
Bank of America Securities
$645.06
Hold
―
Reiterated
07/23/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Argenx Se (NASDAQ: ARGX)
Canaccord Genuity Analyst forecast on MX:HIMS
Maria Ripps
Canaccord Genuity
Canaccord Genuity
$697.36
Buy
―
Reiterated
07/23/26
Hims & Hers Health: Regulatory Tailwinds and Peptide Opportunity Support Buy Rating, $40 Price Target Reiterated
Morgan Stanley Analyst forecast on MX:HIMS
Craig Hettenbach
Morgan Stanley
Morgan Stanley
$366.12
Hold
―
Reiterated
07/22/26
Analysts Offer Insights on Healthcare Companies: Insmed (NASDAQ: INSM), TransMedics Group (NASDAQ: TMDX) and Hims & Hers Health (NYSE: HIMS)
Evercore ISI Analyst forecast on MX:HIMS
Mark Mahaney
Evercore ISI
Evercore ISI
$418.42
Hold
―
Reiterated
05/12/26
Evercore ISI Sticks to Its Hold Rating for Hims & Hers Health (HIMS)
Jefferies Analyst forecast on MX:HIMS
Brian Tanquilut
Jefferies
Jefferies
$444.57→$427.13
Hold
―
Reiterated
05/12/26
Hims & Hers price target lowered to $24.50 from $25.50 at JefferiesHims & Hers price target lowered to $24.50 from $25.50 at Jefferies
TD Cowen Analyst forecast on MX:HIMS
Jonna Kim
TD Cowen
TD Cowen
$400.98→$435.85
Hold
―
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Harrow Health (NASDAQ: HROW), Hims & Hers Health (NYSE: HIMS) and ArriVent BioPharma, Inc. (NASDAQ: AVBP)
J.P. Morgan Analyst forecast on MX:HIMS
Cory Carpenter
J.P. Morgan
J.P. Morgan
$610.19→$575.32
Buy
―
Reiterated
05/12/26
Hims & Hers price target lowered to $33 from $35 at JPMorganHims & Hers price target lowered to $33 from $35 at JPMorgan
Needham Analyst forecast on MX:HIMS
Ryan MacDonald
Needham
Needham
$610.19
Buy
―
Reiterated
05/12/26
Analyst Reaffirms Buy on Hims & Hers, Lifts Price Target to $35 on Long-Term Growth from Novo Partnership
Deutsche Bank Analyst forecast on MX:HIMS
George Hill
Deutsche Bank
Deutsche Bank
$488.15→$435.85
Hold
―
Assigned
05/05/26
Hims & Hers price target lowered to $25 from $28 at Deutsche BankHims & Hers price target lowered to $25 from $28 at Deutsche Bank
Leerink Partners Analyst forecast on MX:HIMS
Michael Cherny
Leerink Partners
Leerink Partners
―
Hold
―
Reiterated
04/16/26
Push to ease peptide restrictions positive for Hims & Hers, says Leerink Push to ease peptide restrictions positive for Hims & Hers, says Leerink
Nephron Analyst forecast on MX:HIMS
Unknown Analyst
Nephron
Not Ranked
Nephron
$610.19
Buy
―
Upgraded
03/09/26
Hims & Hers upgraded to Buy from Hold at Nephron ResearchHims & Hers upgraded to Buy from Hold at Nephron Research
BTIG Analyst forecast on MX:HIMS
David Larsen
BTIG
BTIG
―
Hold
―
Reiterated
03/05/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BBOTBridgeBio Oncology Therapeutics
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hims & Hers Health

3 Months
Maria RippsCanaccord Genuity
Success Rate
11/15 ratings generated profit
73%
Average Return
+23.46%
Copying Maria Ripps's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +23.46% per trade.
1 Year
Ryan MacDonaldNeedham
Success Rate
7/9 ratings generated profit
78%
Average Return
+41.02%
Copying Ryan MacDonald's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +41.02% per trade.
2 Years
Ryan MacDonaldNeedham
Success Rate
7/9 ratings generated profit
78%
Average Return
+41.02%
Copying Ryan MacDonald's trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +41.02% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIMS Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
7
7
1
0
0
Buy
4
5
10
8
10
Hold
31
36
32
21
20
Sell
9
6
0
0
0
Strong Sell
0
0
0
0
0
total
51
54
43
29
30
In the current month, HIMS has received 10 Buy Ratings, 20 Hold Ratings, and 0 Sell Ratings. HIMS average Analyst price target in the past 3 months is 531.01.
Each month's total comprises the sum of three months' worth of ratings.

HIMS Financial Forecast

HIMS Earnings Forecast

Next quarter’s earnings estimate for HIMS is -$0.85 with a range of -$2.79 to $1.57. The previous quarter’s EPS was -$6.97. HIMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.79% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.
Next quarter’s earnings estimate for HIMS is -$0.85 with a range of -$2.79 to $1.57. The previous quarter’s EPS was -$6.97. HIMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.79% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Sales Forecast

Next quarter’s sales forecast for HIMS is $12.18B with a range of $11.97B to $12.86B. The previous quarter’s sales results were $10.60B. HIMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.69% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.
Next quarter’s sales forecast for HIMS is $12.18B with a range of $11.97B to $12.86B. The previous quarter’s sales results were $10.60B. HIMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.69% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Stock Forecast FAQ

What is MX:HIMS’s average 12-month price target, according to analysts?
Based on analyst ratings, Hims & Hers Health, Inc.’s 12-month average price target is 531.01.
    What is MX:HIMS’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:HIMS, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Hims & Hers Health, Inc. a Buy, Sell or Hold?
        Hims & Hers Health, Inc. has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 8 hold ratings and 0 sell ratings.
          What is Hims & Hers Health, Inc.’s share price target?
          The average share price target for Hims & Hers Health, Inc. is 531.01. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $697.36 ,and the lowest forecast is $366.12. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Hims & Hers Health, Inc.?
            Hims & Hers Health, Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.
              How can I buy shares of Hims & Hers Health, Inc.?
              To buy shares of MX:HIMS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.